Objective To explore the clinical and pathological characteristics of intraductal car-cinoma of the prostate(IDC-P)and analyze the mutation status of the BRCA1/2 genes in IDC-P.Methods A retrospective analysis was conducted on the clinical data of 137 patients diagnosed with prostate cancer at the Department of Urology,Wuhan Central Hospital,Affiliated to Tongji Medical College,Huazhong University of Science and Technology,from January 2017 to March 2022.Pa-tients were divided into IDC-P and non-IDC-P groups based on the presence of IDC-P.Preoperative total prostate-specific antigen(tPSA)levels,presence of seminal vesicle invasion,bone metastases,and lymph node metastases were recorded for both groups.Multiparametric magnetic resonance ima-ging was utilized to analyze the prostate imaging reporting and data system nodal scores,clinical T staging,and Gleason scores,which were then compared between the groups.Additionally,the inci-dence of clinically significant mutations in the BRCA1/2 genes within the IDC-P group was statisti-cally analyzed.Results In this study,we identified IDC-P in 15 cases,accounting for 10.95%of the prostate cancer cohort.Patients in the IDC-P group exhibited elevated preoperative tPSA levels,Gleason scores,and clinical T-stages,which increased their susceptibility to bone metastases and se-minal vesicle invasion.Among the 9 patients who underwent radical prostatectomy,none displayed clinically significant muta-tions in the BRCA1/2 genes upon postoperative genetic analysis.Post-surgery,only one patient experienced biochemical recur-rence,with subsequent invasion of the bladder and rectum after 24 months of treatment.Additionally,two patients initially di-agnosed with bone metastases progressed to metastatic castration-resistant prostate cancer within six months of therapy.Con-clusions IDC-P is often more aggressive and has a poor prognosis,but patients with localized IDC-P may benefit from radical surgery supplemented with new endocrine therapy.
关键词
前列腺导管内癌/诊断/预后/治疗/BRCA1/2基因
Key words
Intraductal carcinoma of the prostate/Disgnosis/Prognosis treatment/BRCA1/2 gene
维普
万方数据